Absci Corporation (NASDAQ:ABSI – Get Free Report) shares fell 9.6% on Monday after Guggenheim lowered their price target on the stock from $15.00 to $14.00. Guggenheim currently has a buy rating on the stock. Absci traded as low as $7.29 and last traded at $7.6410. 996,995 shares traded hands during trading, a decline of 77% from the average daily volume of 4,304,985 shares. The stock had previously closed at $8.45.
Several other research analysts also recently issued reports on ABSI. Jefferies Financial Group began coverage on Absci in a research report on Thursday, October 29th. They set a “buy” rating and a $14.00 price objective for the company. Lifesci Capital assumed coverage on Absci in a report on Wednesday, September 9th. They set an “outperform” rating on the stock. Needham & Company LLC raised their price target on Absci from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research reissued a “buy” rating and issued a $16.00 price target on shares of Absci in a report on Thursday. Finally, Wall Street Zen raised Absci from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.90.
Get Our Latest Stock Report on Absci
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC acquired a new stake in shares of Absci during the second quarter worth $10,366,000. Siren L.L.C. purchased a new stake in shares of Absci in the first quarter valued at $5,400,000. Bank of America Corp DE purchased a new stake in shares of Absci in the second quarter valued at $6,560,000. Deutsche Bank AG acquired a new position in Absci in the second quarter valued at $1,591,000. Finally, Artia Global Partners LP acquired a new position in Absci in the second quarter valued at $5,383,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.
Absci Price Performance
The company has a 50-day moving average of $9.65 and a two-hundred day moving average of $6.81. The stock has a market capitalization of $1.33 billion, a PE ratio of -9.86 and a beta of 2.22.
Absci (NASDAQ:ABSI – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.66 million. Absci had a negative return on equity of 61.60% and a negative net margin of 8,451.31%. On average, research analysts forecast that Absci Corporation will post -0.76 EPS for the current fiscal year.
Absci Company Profile
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
Featured Stories
- Five stocks we like better than Absci
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
